Page 6 of 6 FirstFirst ... 456
Results 51 to 54 of 54
Thanks Tree31Thanks

Thread: New Cure For Blindness Priced at $850,000

  1. #51
    Member LT Greenbean's Avatar
    Joined
    Oct 2017
    Posts
    2,822
    Thanks
    510

    From
    south area
    Quote Originally Posted by Miller47 View Post
    Big Pharma OWNS many members of Congress.

    That is where the root of the problem is.

    America has the best politicians that money can buy.

    M O N E Y
    I wish everyone else on both sides were smart enough to get this.

    The Dems LOVE Trump's tax plan. They just have to pretend to hate it.

  2. #52
    Veteran Member Dr Sampson Simpson's Avatar
    Joined
    Nov 2010
    Posts
    22,010
    Thanks
    12259

    Quote Originally Posted by labrea View Post
    the american tax payer funds a lot of early research, then we fund profits with our health care dollar.
    They fund basic research, yes, but that is no where near sufficient. Even after the basic research, maybe identify a target, or maybe the research discovered drug, the company needs to do the rest, which costs many millions. Test safety, how the drug is metabolized, where it goes. Then they have to make modification to make the drug work better, be more available to the desired target, last longer, have less side effects, etc. Then the very expensive clinical trials.

    The basic research takes no risk. They don't put up millions to take the product to the next market. I'm not trying to be rude, but commercializing research from univerisities is what I do and most people are completely ignorant of what goes into it. Most major products come from start ups that get huge investments from people who take the risk with no guaranteed, and hope the company progresses to sell and they can cash out on their investment
    Thanks from bajisima

  3. #53
    Veteran Member Southern Dad's Avatar
    Joined
    Feb 2015
    Posts
    37,778
    Thanks
    7749

    From
    Shady Dale, Georgia
    Quote Originally Posted by LT Greenbean View Post
    I wish everyone else on both sides were smart enough to get this.

    The Dems LOVE Trump's tax plan. They just have to pretend to hate it.
    I'm betting that there won't be a lot of them that refuse to take the higher personal deduction amounts or the increased tax credits.

  4. #54
    Veteran Member
    Joined
    Sep 2013
    Posts
    35,216
    Thanks
    27941

    From
    On a hill
    Quote Originally Posted by Dr Sampson Simpson View Post
    They fund basic research, yes, but that is no where near sufficient. Even after the basic research, maybe identify a target, or maybe the research discovered drug, the company needs to do the rest, which costs many millions. Test safety, how the drug is metabolized, where it goes. Then they have to make modification to make the drug work better, be more available to the desired target, last longer, have less side effects, etc. Then the very expensive clinical trials.

    The basic research takes no risk. They don't put up millions to take the product to the next market. I'm not trying to be rude, but commercializing research from univerisities is what I do and most people are completely ignorant of what goes into it. Most major products come from start ups that get huge investments from people who take the risk with no guaranteed, and hope the company progresses to sell and they can cash out on their investment
    It is a shared risk

    "the revenue-generating potential of orphan drugs [was] as great as for non-orphan drugs, even though patient populations for rare diseases are significantly smaller. Moreover, we suggest that orphan drugs have greater profitability when considered in the full context of developmental drivers including government financial incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory success."
    — Gaze and Breen 2012

    According to a 2014 report, the orphan drug market has become increasingly lucrative for a number of reasons: The cost of clinical trials for orphan drugs is substantially lower than for other diseases —trial sizes are naturally much smaller than for more common diseases with larger numbers of patients. Small clinical trials and little competition place orphan agents at an advantage in regulatory review.[3]

    Tax incentives reduce the cost of development. On average the cost per patient for orphan drugs is "six times that of non-orphan drugs, a clear indication of their pricing power". The cost of per-person outlays are huge and are expected to increase with wider use of public subsidies.[3]

    The 2014 Orphan Drug report stated that the percentage of orphan drug sales as part of all prescription drug sales had been increasing at rapid rate. By 2020 the total was predicted to be $176 billion.[3] Although orphan disease populations are the smallest, the cost of per-patient outlays have been the largest. There pressure on pharmaceuticals which "represent the biggest budgetary drain" has been predicted to increase particularly as more people with rare diseases will be eligible for subsidies —in the United States for example through the Affordable Care Act.[3]

    https://en.wikipedia.org/wiki/Orphan_drug

Page 6 of 6 FirstFirst ... 456

Similar Threads

  1. Replies: 59
    Last Post: 22nd March 2016, 07:41 PM
  2. Color-Blindness Is Counterproductive
    By Babba in forum Racism
    Replies: 0
    Last Post: 14th September 2015, 06:07 AM
  3. Middle class homeowners priced out of the market
    By bajisima in forum Economics
    Replies: 131
    Last Post: 11th April 2014, 07:31 AM
  4. Moral Blindness?
    By conservative in forum Philosophy and Religion
    Replies: 1
    Last Post: 4th November 2007, 02:28 AM
  5. Privatized Veggies priced out of schools
    By Idletime in forum Political Discussion
    Replies: 45
    Last Post: 30th August 2007, 12:58 PM

Tags for this Thread


Facebook Twitter RSS Feed